Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Core Insights - Johnson & Johnson has successfully completed the acquisition of Halda Therapeutics for $3.05 billion in cash, enhancing its oncology portfolio with innovative therapies for solid tumors, including prostate cancer [1][2] Group 1: Acquisition Details - The acquisition of Halda Therapeutics includes the addition of HLD-0915, a clinical-stage therapy for prostate cancer, which utilizes the proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform [2] - The deal is expected to result in a dilution of approximately $0.20 to Adjusted Earnings Per Share (EPS), split equally between 2025 and 2026, due to non-recurring charges related to Halda employee equity awards and integration costs [3] Group 2: Strategic Goals - The acquisition is part of Johnson & Johnson's commitment to redefining cancer treatment through breakthrough science and transformative medicines, aiming to eliminate cancer [2] - The company plans to leverage the RIPTAC™ platform to advance a promising pipeline of novel product candidates and discover more molecules in oncology and beyond [3]